anti-PSMA gamma delta T-cell engaging bispecific antibody LAVA-1207

A bispecific gamma delta T-cell engager (TCE) antibody targeting both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and Vdelta2 on Vgamma9Vdelta2 T cells, with potential immunostimulating and antineoplastic activities. Upon administration, anti-PSMA gamma delta T-cell engaging bispecific antibody LAVA-1207 binds to both PSMA-expressing tumor cells and Vgamma9Vdelta2 T cells. This activates and redirects the Vgamma9Vdelta2 T cells to PSMA-expressing tumor cells, and the Vgamma9Vdelta2 T cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, the Vgamma9Vdelta2 T cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. The Vdelta2 gamma delta T-cell subset is one of the two major gamma delta T-cell subsets that is almost exclusively paired with the Vgamma9 chain. PSMA, a type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.